TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01526590
Drug: Definity Contrast
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: While the patient is still sedated from their EUS and before tissue sampling, the patient will receive a dose of Definity intravenously through their peripheral IV access after being agitated. The dose of Definity will be 10 microliters/kg given in one to two doses, and will not exceed 2cc.
Study: NCT04164823
Drug: Analgesic self-medication (OTC)
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will note the usual analgesic self-medication used to relief pain (ibuprofen, acetaminophen...).
Study: NCT01706575
Drug: Nucleos(t)ide Analogues (NA)
Normalized name: levothyroxine sodium Oral Tablet [Levo-T]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nucleos(t)ide analogues includes adefovir, entecavir, lamivudine or tenofovir.
Study: NCT00227500
Drug: Pravastatin
Normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00819078
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: no dosage
Study: NCT02454556
Drug: FOLITIME®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02454556
Drug: Gonal-F®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00236275
Drug: Fluoro-L-thymidine-(18F)
Normalized name: L-thymidine
DrugBank: Telbivudine (DB01265)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fluoro-L-thymidine-(18F)
Study: NCT00925652
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00925652
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00785798
Drug: Pegylated Liposomal Doxorubicin (PLD), Doxil
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV 30mg/m2 on day 3 of a 21-day cycle
Study: NCT01599078
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline will be administered intra-arterially via the TAPAS catheter following percutaneous revascularization. The dwell time will be 5minutes.
Study: NCT00003754
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00093847
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to be taken daily for 6 weeks
Study: NCT04624776
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: A bolus infusion of 4 mL isotonic saline (NaCl 0.9%).
Study: NCT02795520
Drug: OTS167IV
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00283920
Drug: [(11)C] PBR28
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00484198
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivoglitazone-matching placebo administered as a tablet orally, once daily or a pioglitazone-matching placebo administered as an over-encapsulated tablet orally, once daily capsule
Study: NCT03090698
Drug: Hylan G-F 20
Normalized name: hylan G-F 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: intra-articular administration
Study: NCT04588727
Drug: AZD3366
Approvals — FDA: no, EMA: no, PMDA: no
Description: In Part A, subjects will be randomized to receive intravenous infusion AZD3366 dose 1-7, single ascending dose (SAD). In Part A, Dose 2-7 may be adjusted based on PK data from previous cohort\[s\]. In Part B, subjects will be randomized to receive intravenous infusion AZD3366 dose X (a dose resulting in predicted therapeutic exposure).
Study: NCT04588727
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: In Part A and Part B, subjects will be randomized to receive intravenous infusion of placebo (0.9% sodium chloride solution).
Study: NCT04588727
Drug: acetylsalicylic acid (ASA)
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In Part B, subjects will receive oral ASA chewable tablets.
Study: NCT00197444
Drug: CDGP/5-FU combined with radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose of Nedaplatin (CDGP) 10 mg/body/day was daily administered on day 1-5, 8-13, 15-19, 22-26 and 5-FU 500 mg/body/day was continuously administered on day 1-5, 8-13, 15-19, 22-26.
Study: NCT01210144
Drug: Gonal -f® [r-hFSH]
Approvals — FDA: no, EMA: no, PMDA: no
Description: On Day 2 of the menstrual cycle, a pre-defined fixed dose of 150 International Units (IU) per day of recombinant human follicle stimulating hormone (r-hFSH) will be administered until follicles are recruited and developed.
Study: NCT01210144
Drug: Ovitrelle® [r-hCG alfa]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ovulation triggering will be performed using a single injection of 250 microgram (mcg) recombinant human chorionic gonadotropin (r-hCG) alfa as soon as follicles satisfy the criteria for follicular development, that is at least 3 follicles greater than (\>) 16 millimeter (mm), and with estradiol (E2) \> 1 microgram per liter (mcg/L) if gonadotropin releasing hormone (GnRH) agonist will be used.
Study: NCT01210144
Drug: Gonadotropin-releasing hormone (GnRH) Agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: To prevent premature ovulation in participants undergoing a controlled ovarian stimulation (COS), 0.1 milligram (mg) GnRH agonist daily will be given after endometrial biopsy, 7 days after the peak day of luteinizing hormone (Day LH + 7) as per summary of product characteristics (SmPC), in long agonist protocol.
Study: NCT00435019
Drug: insulin NPH
Normalized name: insulin NPH human isophane
Approvals — FDA: no, EMA: no, PMDA: no
Description: s.c. injection, once or twice daily.
Study: NCT00657306
Drug: hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 50 mg/6 h per day
Study: NCT00657306
Drug: dextrose solution 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: dextrose solution 5% 100 ml/6 h per day
Study: NCT03462459
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule containing inert (nonactive) material to mimic 125 mg vancomycin capsule
Study: NCT00403845
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to indacaterol was provided in powder filled capsules with a single dose dry powder inhaler (SDDPI).
Study: NCT01465633
Drug: levothyroxine
Normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03053427
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration
Study: NCT01557322
Drug: methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: This is a Non-interventional study. The data is being analyzed retrospectively. The data consists of 2 cohorts; biologic and non-biologic
Study: NCT04531163
Drug: N Acetylcysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: (NAC) is a drug used in the experiment and participant are treated with it by 1200mg/day dose for two months.
Study: NCT01359267
Drug: 99mTc-EC-DG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 99mTc-EC-DG will be used before the SPECT/CT scans throughout the study to determine the its effectiveness. 20 mCi of 99mtc-EC-DG will be administered through a vein through a catheter. This will be done before the SPECT/CT scan at 4 weeks and 10 weeks.
Study: NCT02071082
Drug: E/C/F/TAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: E/C/F/TAF (150/150/200/10 mg) FDC tablet administered orally once daily with food
Study: NCT00865943
Drug: CELEXATM 10 mg tablets, single dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: B: Active comparator Subjects received Forest Pharmaceuticals, Inc. marketed products under fasting conditions
Study: NCT02334176
Drug: lidocaine 1.5% with epinephrine 5µg/ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35 ml of lidocaine 1.5% with epinephrine 5µg/ml will be used to perform the axillary plexus block
Study: NCT00431873
Drug: MGCD0103
Approvals — FDA: no, EMA: no, PMDA: no
Description: MGCD0103 Administered orally three times per week.
Study: NCT02404389
Drug: Investigational Treatment
Normalized name: INVESTIGATIONAL AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application for two treatment cycles with twice daily applications, separated by a 4 week treatment pause and followed by 8 week treatment free follow-up.
Study: NCT00925821
Drug: RAD
Normalized name: Durad
Approvals — FDA: no, EMA: no, PMDA: no
Description: After enrollment, patients are to receive four cycles of RAD induction treatment: a combination of lenalidomide (Revlimid), adriamycin, and dexamethasone.
Study: NCT00576732
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution qd or bid for 6 weeks
Study: NCT03219008
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine is one kind of selective serotonin reuptake inhibitor(SSRIs), whose effect is much better than other non-underload subtypes compared with underload subtypes.So patients would be treated with fluoxetine only.
Study: NCT04305002
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injections, once weekly for 18 months
Study: NCT03339336
Drug: BIIB074
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm.
Study: NCT03339336
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm.
Study: NCT02101359
Drug: Mydriatics
Normalized name: prednisolone and mydriatics
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 drops of tropicamide and phenylephrine were instilled 30 minutes before surgery. The second and the third instillation of both phenylephrine and tropicamide will be realised respectively within 20 and 10 minutes before surgery.
Study: NCT02465996
Drug: Puyuanhewei
Approvals — FDA: no, EMA: no, PMDA: no
Description: FD patients willing to receive Puyuanhewei were given 4 pills three times a day regardless of PDS or EPS for 4 weeks after pCLE examination.
Study: NCT00756600
Drug: General Anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sevoflurane for induction and maintenance of general anesthesia, dose up to 8% inspired for duration of procedure plus bupivacaine local anesthetic blockade (up to 2.5 mg/kg) administered via caudal or ilioinguinal nerve block.
Study: NCT04620954
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegylated liposomal doxorubicin (PLD) and carboplatin are administered every 4 weeks through IV. The starting dose of PLD and carboplatin are 30mg/m\^2 and 5 AUC (Area Under the Curve) respectively.
Study: NCT01330953
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous placebo dose.
Study: NCT01330953
Drug: LY2928057
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous dose.
Study: NCT02547974
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses at Day 0 and Day 60, Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule
Study: NCT00874562
Drug: Corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial dose of corticosteroid given intravenously. After the first dose, corticosteroid will be taken orally every 8 hours for the duration of the five-day period
Study: NCT03040427
Drug: F-18 florbetapir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac PET images will be obtained following injection of F-18 labeled Florbetapir (Trade Name: Amyvid).
Study: NCT02577367
Drug: Levothyroxine
Normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administer Levothyroxine
Study: NCT02109172
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02899533
Drug: [18F] FES
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[18F\] FES PET/CT scan, imaging tracer
Study: NCT01667367
Drug: RG1662
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose
Study: NCT01667367
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose
Study: NCT00226512
Drug: Campath-1H /ATG
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02094521
Drug: NNC0113-0987
Approvals — FDA: no, EMA: no, PMDA: no
Description: For oral administration. All subjects will be treated for 10 consecutive days with five days on 5 mg NNC0113-0987 followed by five days on 10 mg NNC0113-0987. Dose escalation is chosen to increase gastrointestinal tolerability.
Study: NCT02826525
Drug: AZD4076
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational product
Study: NCT02826525
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control
Study: NCT01874145
Drug: GA 40 mg/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glatiramer acetate (GA) 40 mg/mL subcutaneous (SC) injection, is a single-use pre-filled syringe (PFS) containing 1.0 ml of a clear, colorless to slightly yellow, sterile, non-pyrogenic solution.
Study: NCT03840993
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: over 16 weeks
Study: NCT00551954
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: one tablet t.i.d.
Study: NCT01602900
Drug: GSK356278
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational Medicinal Product
Study: NCT02233699
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00004250
Drug: isolated limb perfusion
Normalized name: ISOLATE
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00022399
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400mg PO twice daily for 4-6 weeks up to 8 hours prior to prostatectomy.
Study: NCT00402337
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral, once daily
Study: NCT04226495
Drug: Sufentanil Infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-operative sufentanil infusion
Study: NCT04226495
Drug: Sufentanil Bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-operative sufentanil bolus
Study: NCT01779492
Drug: GL2907
Approvals — FDA: no, EMA: no, PMDA: no
Description: once a day
Study: NCT02016365
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg/day (100 mg twice daily, orally) for 4 weeks with a pause of 2 weeks in combination with UDCA
Study: NCT00475514
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02596217
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC injection (stage 1)
Study: NCT02596217
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion (stage 2)
Study: NCT02009332
Drug: ABI-009
Normalized name: PICEA ABIES WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABI-009 is a nanoparticle albumin-bound (nab®) formulation of the mammalian Target of Rapamycin ( mTOR) inhibitor, sirolimus. Specifically, ABI-009 is a sterile lyophilized powder of albumin-bound sirolimus nanoparticles with a mean particle size of less than 100 nm.
Study: NCT04276649
Drug: Caltrate
Normalized name: Caltrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in supplementary group were received with Caltrate 0.6 g/d and Mesalazine 4g/d orally at least 12 months, and those in non-supplementary only take Mesalazine 4g/d.
Study: NCT01714609
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Comparator: Placebo
Study: NCT00795639
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitaxsentan Placebo = 1 tablet administered orally, once daily
Study: NCT01074996
Drug: S-1 plus Leucovorin
Normalized name: (S)-Leucovorin
DrugBank: (6R)-Folinic acid (DB03256)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 40-60mg bid, days 1-14 , every 3 weeks Leucovorin 25mg bid , days 1-14 , every 3 weeks
Study: NCT03796364
Drug: standard SRILI treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in the control group were treated with current routine radiation pneumonia. At week 2, 4, 6, 12, 24, 36, 52, lung functional and blood oxygen saturation was measured, chest CT and the St. George Respiratory Questionnaire (SGRQ) were assessed for quality of life at week 12, 24, 52 and before treatment; collecting the related observation indexes of patients; primary endpoint; recrudescence rate of RP; secondary endpoints; remission rate of RP and incidence rate of RF; incidence rate of RF; number of acute exacerbations and quality of life.
Study: NCT00034944
Drug: Comparator: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03283059
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Tablet: P.O. tid
Study: NCT04747951
Drug: consolidation chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of oxaliplatin (130 mg/m2 over 2 h) on day 1 and oral administration of capecitabine (1000 mg/m2 twice daily) from day 1 to day 14, is repeated every 3 weeks for 3 courses, 3 weeks per course
Study: NCT04631705
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of DZIF-10c diluent as placebo
Study: NCT04631705
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of sterile normal saline (NaCl 0.9%) as placebo
Study: NCT04747951
Drug: adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of l-LV (400 mg/m2) and oxaliplatin (85 mg/ m2) by intravenous infusion over 2 h, followed by rapid intravenous infusion (iv) of 5-FU (400 mg/m2) and then slow infusion (civ) of 5-FU (2400 mg/m2 over 46 h), is repeated every 2 weeks for 6-12 cycles
Study: NCT00649402
Drug: Lotrel® Capsules 10 mg/20 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10/20mg, single dose fed
Study: NCT03374722
Drug: Opioids
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanically ventilated critically ill patients who receive continuous opioid infusion for more than 24 hours will be observed for withdrawal symptoms when rate of opioid infusion is disrupted or decreased
Study: NCT04480333
Drug: Drug: NA-831 - 0.20 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: NA-831 in nanoparticle inhalation formulation
Study: NCT04480333
Drug: Placebo- 0.20 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in nanoparticle inhalation formulation
Study: NCT04480333
Drug: Drug: GS-5734 - 1.00 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: GS-5734 in nanoparticle inhaled formulation
Study: NCT04480333
Drug: Placebo- 1.00 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in nanoparticle inhalation formulation
Study: NCT04480333
Drug: Drug: GS-5734 - 2.00 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: GS-5734 in nanoparticle inhaled formulation
Study: NCT04480333
Drug: Placebo- 2.00 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in nanoparticle inhaled formulation
Study: NCT01318356
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antibiotic therapy will consist of doxycycline once daily 200 mg (in 1 capsule) for 24 weeks. Patients will be monitored 4, 8, 16 and 26 weeks after start for side effects (rash, liver enzymes). Antibiotics will be stopped in case of side effects or pregnancy.
Study: NCT01318356
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in the placebo group will receive once daily 1 placebo capsule identical in appearance to the doxycycline for 24 weeks and have the same visits and monitoring for side effects as the patients randomized to doxycycline (Patients will be monitored 4, 8, 16 and 26 weeks)
Study: NCT00555022
Drug: GSK1160724
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1160724 will be available with dosing strengths of 10, 50 and 125 micrograms/blister for inhalation using the DISKUS inhaler.
Study: NCT00000448
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A placebo is a simulated or otherwise medically ineffectual treatment for a disease or other medical condition intended to deceive the recipient.
Study: NCT00555022
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive placebo.
Study: NCT02597465
Drug: SPARC1507
Approvals — FDA: no, EMA: no, PMDA: no
Description: The administered dose is calculated based on the BSA calculated for the subject on Day 1 of the Cycle
Study: NCT02597465
Drug: Reference1507
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigators choice including chemotherapy or supportive therapy
Study: NCT04392830
Drug: ALZ002 DS
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT04392830
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT00688922
Drug: Pravastatin
Normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Take an initial dose of pravastatin to start as 10mg/day, which is the recommended initial dose by Health, Labour and Welfare Ministry of Japan, and a diet counseling.
Study: NCT01886781
Drug: Placebo comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micro-crystalline cellulose powder, identical taste, texture and appearance
Study: NCT00952523
Drug: Tretinoin Facial Gel
Normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A marketed facial gel containing Tretinoin 0.04% is applied to one side of the face daily for three weeks.
Study: NCT04534114
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo to BAY2976217 will be injected subcutaneously.
Study: NCT04463004
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusion
Study: NCT04247256
Drug: FOLFIRI Protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFIRI standard treatment on day 5 to 7 (both days included) of a 14 day period. repeated bi-weekly
Study: NCT04236921
Drug: DopaSnap®
Approvals — FDA: no, EMA: no, PMDA: no
Description: immediate release CD/LD 25/100mg; Riverside Pharmaceuticals Corporation, USA
Study: NCT00399763
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half of participants are randomized to placebo plus individual cognitive behavioral therapy targeting substance use disorder
Study: NCT00240292
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02205801
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00457639
Drug: Cholic Acid
Normalized name: Cholic Acid
DrugBank: Cholic Acid (DB02659)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Capsules of active Cholic Acid or matching placebo, total dose is 15 mg/kg per day, maximum dose of 1500 mg per day, taken PO, BID.